Ligand and Genagon ink drug development agreement

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ JacobStudio)
(Image: Getty/ JacobStudio)

Related tags: Drug development, Drug development process, Preclinical contract research, preclinical, Preclinical services, Antibody, models, Immuno-oncology, Drug discovery

Ligand Pharmaceuticals enters an agreement with Genagon to provide access to its drug development platform capable of producing fully human antibodies.

Per the agreement, Genagon, a Swedish biotech focused on immuno-oncology development, will gain access to the Ligand’s full OmniAb platform for drug discovery which includes: OmniRat, OmniMouse, OmniFlic, and OmniChicken.

Genagon will use this access to develop antibody-based therapeutics for immuno-oncology targeting suppressive pathways on antigen presenting cells that the company has discovered.

John Higgins, CEO, Ligand said in a statement, “The OmniAb platform is innovative and it has proven itself to be a broadly-licensable technology that we will continue to leverage as we build our Shots-on-Goal business model.”

Higgins added that the platform is the only of its kind to offer access to “three species that produce fully-human antibodies.”

Ligand received an upfront payment and is eligible to receive development milestone payments and tiered royalties for each product incorporating an OmniAb-derived antibody. Genagon will be responsible for costs related to their programs.

Related news

Related products

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers

Follow us


View more